Neutrophil‑to‑lymphocyte ratio and risk of disease progression in patients with nivolumab‑treated unresectable or recurrent gastric cancer.
Hayashi H, Yasufuku I, Sato Y, Fujibayashi S, Chikaishi W, Endo M, Horaguchi T, Yokoi R, Matsumoto K, Kuno M, Sengoku Y, Fukada M, Asai R, Tajima JY, Makiyama A, Kiyama S, Tanaka Y, Murase K, Ishihara T, Matsuhashi N.
Hayashi H, et al. Among authors: sato y.
Oncol Lett. 2024 Oct 22;29(1):20. doi: 10.3892/ol.2024.14766. eCollection 2025 Jan.
Oncol Lett. 2024.
PMID: 39492934
Free PMC article.